PANews reported on August 4th that Hanyu Pharmaceuticals and digital asset platform KuCoin officially signed a letter of intent for a strategic partnership, citing Zhitong Finance's report on Hanyu Pharmaceuticals. The two parties intend to jointly explore and promote mainland China's first RWA tokenization pilot project in Hong Kong, with the underlying asset being "future revenue rights from innovative drug R&D." According to the agreement, Hanyu Pharmaceuticals will leverage its technological expertise and R&D pipeline in the field of blockbuster GLP-1 peptide drugs as the underlying asset, while KuCoin will leverage its strengths in blockchain technology, full-process RWA solutions, and global compliance resources to provide integrated support for the project, including on-chain mapping, asset tokenization, transaction matching, and revenue distribution.